Clinical Trial Update: Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab [Phase 2]

View source ↗

Summary

Phase 2 trial comparing secukinumab to guselkumab in clearing psoriatic plaques refractory to ustekinumab has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)
• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2021-02-25